Bronchodilator therapy for chronic cough.
Matera MG, Rogliani P, Zanasi A, Cazzola M.
Pulm Pharmacol Ther. 2017 Dec;47:88-92. doi: 10.1016/j.pupt.2017.05.011. Epub 2017 May 17.
Updated bronchodilator analysis.
Wang EE, Kellner JD, Ohlsson A, Gadomski AM.
Arch Pediatr Adolesc Med. 1999 Apr;153(4):430.
Pirbuterol.
Crompton GK, Grant IW.
Lancet. 1984 Apr 7;1(8380):795. doi: 10.1016/s0140-6736(84)91309-6.
Bronchiolitis.
Bourke T, Shields M.
BMJ Clin Evid. 2011 Apr 11;2011:0308.
Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations.
Calverley PM, Albert P, Walker PP.
Lancet Respir Med. 2013 Sep;1(7):564-73. doi: 10.1016/S2213-2600(13)70086-9. Epub 2013 Jun 18.
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.
Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M.
Lancet Respir Med. 2018 Feb;6(2):117-126. doi: 10.1016/S2213-2600(18)30006-7. Epub 2018 Jan 10.
Inhaled bronchodilator administration during mechanical ventilation.
Duarte AG.
Respir Care. 2004 Jun;49(6):623-34.
Bronchodilator effect on regional lung function in pediatric viral lower respiratory tract infections.
Strodthoff C, Kähkönen T, Bayford RH, Becher T, Frerichs I, Kallio M.
Physiol Meas. 2022 Oct 18;43(10). doi: 10.1088/1361-6579/ac9450.
Dueling meta-analyses.
Wears RL.
Ann Emerg Med. 2000 Sep;36(3):234-6. doi: 10.1067/mem.2000.109692.
Meaningful placebos--controlling the uncontrollable.
Moerman DE.
N Engl J Med. 2011 Jul 14;365(2):171-2. doi: 10.1056/NEJMe1104010.
